Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ionis Pharmaceuticals, Inc. - Common Stock (NQ:IONS)

70.86 -0.64 (-0.90%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Ionis Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Capricorn Buys New Stake in Ionis Pharmaceuticals (IONS) With 163,000 Shares
Via The Motley Fool
31 Analysts Assess Ionis Pharmaceuticals: What You Need To Know
 
Via Benzinga
IONIS PHARMACEUTICALS INC (NASDAQ:IONS) Shows Strong Growth Momentum and Technical Strength
IONIS Pharmaceuticals stock shows strong technical and fundamental momentum, meeting strict trend-following criteria with surging earnings and revenue growth. 
Via Chartmill
Ionis Pharmaceuticals (NASDAQ:IONS) Ascends to Six-Year High, Fueled by Breakthrough Pipeline and Robust Sales Outlook
Carlsbad, CA – October 8, 2025 – Ionis Pharmaceuticals (NASDAQ:IONS) is currently witnessing a remarkable surge in its stock value, nearing a six-year high. This impressive ascent is largely driven by... 
Via MarketMinute
Ionis Pharma Stock Rises After Multiple Price Target Hikes On Heels Of Positive Study Results In Alexander Disease
Via Stocktwits
Retail Traders Pile Into Ionis As Wall Street Hikes Price Targets On FDA Approval Of Swelling Disorder Therapy
Via Stocktwits
Why Ionis Stock, Approaching A Six-Year High, Just Snagged A Price-Target Hike
The company is working toward a potential $5 billion sales peak for its partnered and unpartnered programs. 
Via Investor's Business Daily
This Penumbra Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday
 
Via Benzinga
What Analysts Are Saying About Ionis Pharmaceuticals Stock
 
Via Benzinga
Ionis Pharmaceuticals Reveals 'Unprecedented Results' From Rare Neurological Disease Trial
Ionis reports positive pivotal study results for zilganersen in Alexander disease, showing gait speed benefits and strong safety data. 
Via Benzinga
Ionis Pharmaceuticals To Expedite Development Of Rare Neurological Disease Candidate With FDA Breakthrough Status
FDA designates Ionis Breakthrough Therapy for Angelman syndrome after Phase 1/2 results showed functional improvements. 
Via Benzinga
Earnings Scheduled For July 30, 2025
 
Via Benzinga
An Overview of Ionis Pharmaceuticals's Earnings
 
Via Benzinga
Here are the top movers in Tuesday's session.
Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes. 
Via Chartmill
IONS Stock Soars 34% To Hit February 2021 Highs After Medicine Shows Positive Effect On Elevated Triglyceride Levels In Late-Stage Studies
In two studies, Ionis’ Olezarsen demonstrated a highly statistically significant placebo-adjusted mean reduction in fasting triglycerides of up to 72% at six months. 
Via Stocktwits
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
Air Lease, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday
 
Via Benzinga
Ionis Pharma's Investigational Drug Shows Promise For Triglyceride And Pancreatitis Reduction
Ionis posted positive Phase 3 results for olezarsen in severe hypertriglyceridemia, showing 72% triglyceride reduction and 85% fewer pancreatitis events. 
Via Benzinga
There are notable gap-ups and gap-downs in today's session.
The session on Tuesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session. 
Via Chartmill
Ionis Pharma Hits The 'Bull Case,' 'Blue Sky' In Lowering Triglycerides. Shares Launch.
Ionis Pharmaceuticals scored the "bull case" Tuesday after its experimental treatment for high triglycerides beat the placebo. 
Via Investor's Business Daily
IONIS PHARMACEUTICALS INC (NASDAQ:IONS) Presents a High-Probability Technical Breakout Setup
IONIS Pharmaceuticals (IONS) shows strong technicals with a high setup rating, signaling a potential breakout from its current consolidation pattern. 
Via Chartmill
What's Going On With Takeda Stock On Friday?
Takeda stock steadies after early dip as FDA clears Ionis' Dawnzera for hereditary angioedema, posing fresh competition to Takeda's Takhzyro. 
Via Benzinga
Beyond The Numbers: 10 Analysts Discuss Ionis Pharmaceuticals Stock
 
Via Benzinga
Ionis Pharma Wins FDA Nod For First RNA-Targeted Therapy For Rare Genetic Swelling Disorder
FDA approved Ionis' Dawnzera for hereditary angioedema, showing up to 87% attack reduction and strong results in switch patients. 
Via Benzinga
IONS Premarket Gains 2.4% After C-Suite Insider Sells $440K In Stock
Ionis Pharmaceuticals rose 2.38% after hours following a planned stock sale by its chief scientific officer under a Rule 10b5-1 plan. 
Via Benzinga
Ionis (IONS) Q2 Revenue Soars 101%
Via The Motley Fool
Deep Dive Into Ionis Pharmaceuticals Stock: Analyst Perspectives (6 Ratings)
 
Via Benzinga
Ionis (IONS) Q2 2025 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Ionis Posts Surprise Q2 Profit, Double Revenues On Stronger Sales From Newly Approved Genetic Disease Drug
Ionis reports surprise Q2 profit, raises 2025 forecast after strong Tryngolza launch and royalty gains push revenue past expectations. 
Via Benzinga
IONIS PHARMACEUTICALS INC (NASDAQ:IONS) - A Strong Technical Setup Worth Watching
IONIS Pharmaceuticals (NASDAQ:IONS) shows strong technicals with an 8/10 rating and a high-quality setup pattern, making it a breakout candidate for traders. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.